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Abstract
Background: AMP-activated protein kinase (AMPK) is a fuel-sensing enzyme that is activated when cells experience
energy deficiency and conversely suppressed in surfeit of energy supply. AMPK activation improves insulin
sensitivity via multiple mechanisms, among which AMPK suppresses mTOR/S6K-mediated negative feedback
regulation of insulin signaling.
Results: In the present study we further investigated the mechanism of AMPK-regulated insulin signaling. Our
results showed that 5-aminoimidazole-4-carboxamide-1 ribonucleoside (AICAR) greatly enhanced the ability of
insulin to stimulate the insulin receptor substrate-1 (IRS1)-associated PI3K activity in differentiated 3T3-F442a
adipocytes, leading to increased Akt phosphorylation at S473, whereas insulin-stimulated activation of mTOR was
diminished. In 3T3-F442a preadipocytes, these effects were attenuated by expression of a dominant negative
mutant of AMPK a1 subunit. The enhancing effect of ACIAR on Akt phosphorylation was also observed when the
cells were treated with EGF, suggesting that it is regulated at a step beyond IR/IRS1. Indeed, when the cells were
chronically treated with AICAR in the absence of insulin, Akt phosphorylation was progressively increased. This
event was associated with an increase in levels of phosphatidylinositol -3,4,5-trisphosphate (PIP3) and blocked by
Wortmannin. We then expressed the dominant negative mutant of PTEN (C124S) and found that the inhibition of
endogenous PTEN per se did not affect phosphorylation of Akt at basal levels or upon treatment with AICAR or
insulin. Thus, this result suggests that AMPK activation of Akt is not mediated by regulating phosphatase and
tensin homologue (PTEN).
Conclusion: Our present study demonstrates that AMPK exerts dual effects on the PI3K pathway, stimulating
PI3K/Akt and inhibiting mTOR/S6K.
Background
AMP-activated protein kinase (AMPK) is a heterotri-
meric enzyme consisting of an a catalytic subunit
(a1, a2), and b (b1, b2) and g (g1, g2, g3) regulatory
subunits [1]. The activation of AMPK occurs by binding
of 5’ AMP to the g subunit and phosphorylation of
T172 in the activation loop of the a catalytic subunit by
upstream kinases such as LKB1 and CaMKK [1]. AMPK
is activated in response to hypoxia, glucose deprivation,
and muscle exercise, under which the AMP to ATP
ratio is increased. In addition, AMPK activity is
increased by certain hormones, such as leptin and adi-
ponectin, and by pharmacological agents, including
5-aminoimidazole-4-carboxamide-1 ribonucleoside
(AICAR), metformin, and thiazolidinediones. These
agents are used in treating insulin resistance in animal
models and/or in humans with type 2 diabetes and its
complications [1].
AMPK exerts pleiotropic effects on cellular metabo-
lism and has been emerged as a therapeutic target for
the metabolic syndrome [2]. The activation of AMPK
improves insulin resistance by stimulating glucose
uptake and lowering blood glucose and lipid levels,
whereas the activity of AMPK is suppressed in disorders
associated with insulin resistance [2,3]. On the other
hand, it increases fatty acid oxidation and inhibits fatty
acid and protein synthesis, which is apparently opposite
to the insulin action [3]. The latter often concurs with
the scenarios when cells confront energy crisis. At mole-
cular levels, complex relationship exists between the
AMPK and insulin signaling pathways. For instances,
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Akt/PKB [7-12], while insulin and Akt have negative
impacts on AMPK activation [13-15].
The major effector of insulin is phosphoinositide
3-kinase (PI3K), which is activated by binding of the
p85 regulatory subunit to specific sites on IRS1/IRS2
that are tyrosine-phosphorylated by the insulin receptor
[16]. Activated PI3K phosphorylates phosphatidylinositol
[4,5]-bisphosphate (PIP2) at 3’ position, whereas phos-
phatase and tension homologue (PTEN) dephosphory-
lates this site and thus turns off the signal. Increased
PIP3 recruits PDK1 and Akt to the plasma membrane
whereby Akt is activated and becomes a major player of
insulin action. An important modulator of inulin action
is the mammalian target of rapamycin (mTOR), a mem-
ber of the phosphoinositide kinase-related family that
possesses exclusively protein kinase activity. mTOR
functions in a mitogenic pathway downstream of PI3K
and is activated by insulin and other mitogens in the
presence of sufficient nutrients such as amino acids and
glucose [17]. Activated mTOR regulates protein synth-
esis via phosphorylation of its targets, such as activation
of S6 kinase 1 (S6K1) and inhibition of the initiation
factor 4E binding protein (4E-BP1). In addition, mTOR
and S6K1 have been shown to induce serine/threonine
phosphorylation of IRS1 to attenuate signal flow to
downstream effectors, and thus play a role in insulin
resistance [18]. In contrast, when cells sense a shortage
of nutrients, for instance, reduced cellular levels of glu-
cose, or other stresses that deplete intracellular ATP,
mTOR is inhibited and protein synthesis slows down,
allowing ATP to be used for processes more critical to
survival. This event is largely controlled by AMPK [3].
In fact, many studies have shown that the activation of
AMPK leads to an inhibitiono fm T O R / S 6 K 1[ 1 9 ] .T h i s
occurs via phosphorylation of TSC2, an mTOR inhibitor
[20,21], and Raptor, a scaffold protein of TORC1, essen-
tial for mTOR activity [22].
Despite the fact that AMPK activation enhances insu-
lin sensitivity, the underlying mechanisms are not fully
delineated. In the present study, we have investigated
the interrelationship between AMPK and insulin signal-
ing. Our results show that AMPK enhances activation of
Akt by insulin, whereas it causes attenuation of mTOR/
S6K1 signaling, both of which are beneficial to insulin
action. Furthermore, our data indicate that AMPK acti-
vation also leads to increased phosphorylation of Akt
through a novel mechanism dependent on PI3K but
independent of PTEN.
Results
Effects of AICAR on insulin signaling
To evaluate the effect of AMPK activation on insulin
signal transduction, 3T3-F442a adipocytes were treated
w i t hA I C A R( 1m M ,2h ) ,f o l l o w e db yi n s u l i n( 1 0 0n M ,
15 min), and IRS1-associated PI3K activity examined. As
s h o w ni nF i g u r e1 A ,w h i l e AICAR treatment caused a
slight inhibition of IRS1-associated PI3K activity at the
basal level, it augmented the activity by almost 2-fold in
the cells treated with insulin. Concurrently, pretreat-
ment with AICAR enhanced insulin-stimulated phos-
phorylation of Akt at S473 by 90% (Figure 1B), which
was accompanied by an increase in phosphorylation of
GSK3 (data not shown). In contrast, insulin-stimulated
phosphorylation of S6K1 was markedly suppressed by
AICAR (Figure 1B). Similar results were obtained in dif-
ferentiated 3T3-L1 adipocytes (data now shown)
Dominant negative mutant of AMPK a1 subunit
diminishes the effect of AICAR
To ascertain if the effects of AICAR are mediated by
AMPK, we established stable cell lines in 3T3-F442a
preadipocytes using a lentiviral system expressing a
dominant negative AMPK a1 catalytic subunit (D157A
mutation) [23]. We then assessed the effect of this
mutant on AICAR-regulated phosphorylation of S473
on Akt in preadipocytes. One reason to use preadipo-
cytes in this and the following experiments is that the
ability of the preadipocytes expressing the mutant to dif-
ferentiate into adipocytes is much greater than that in
presence of the empty vector. As a result, it was difficult
to compare the effects of insulin and AICAR in adipo-
cytes differentiated from these two cell lines, owing to
different expression levels of IRS1, insulin receptors, and
AMPK (Data not shown). A second reason is that the
expression of the dominant negative mutant somehow
decreases the level of endogenous AMPKa subunits
(Figure 2B), which seems to work as a true dominant
negative interfering mutant. As shown in Figure 2A, the
expression of the a1 mutant markedly inhibited insulin-
stimulated Akt phosphorylation and also prevented the
increase in the cells pretreated with AICAR. In contrast,
mTOR/S6K1 signaling changed in an opposite direction,
as manifested by the result that the a1m u t a n tp r e -
vented the reduction of S6K1 and S6 phosphorylation
(Figure 2A). Thus, we conclude that the effects of
AICAR on insulin signaling are mediated by AMPK.
AMPK regulates Akt phosphorylation independent of IRS1
but dependent on PI3K
To seek after the factor that mediates AMPK-induced acti-
vation of Akt, we treated 3T3-F442a preadipocytes with
EGF, which activates Akt independent of IRS1. As shown
in Figure 3A, the dominant negative mutant of AMPK dis-
played a similar inhibitory effect on EGF-stimulated Akt
phosphorylation. By comparing the phospho-signal inten-
sity, we noticed that the Akt phosphorylation by EGF was
much weaker than that by insulin (Data not shown).
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enhanced Akt phosphorylation when the cells were incu-
bated with AICAR alone for 2 hours, which was blunted
by the dominant negative AMPK mutant. This suggests
that AMPK induces Akt activation independent of IRS1.
To confirm the direct effect of AMPK activation on
Akt phosphorylation, we chronically treated the preadi-
pocytes with AICAR and assessed the phosphorylation
of Akt. As shown in Figure 3B, AICAR progressively
increased phosphorylation of S473, reaching the maxi-
mum after 4 h. This was abrogated by expression of the
dominant negative mutant of AMPK.
Next, we examined if AMPK activation upregulates
intracellular levels of PIP3. In doing so, the cells were
treated with AICAR, as compared with insulin, and
immunofluorescently stained with anti-PIP3 antibody.
The data showed that the treatment of the cells with
AICAR for 4 hours increased the abundance of PIP3 to
a level similar to that induced by insulin (Figure 4A),
whereas the effect of AICAR was almost completely
suppressed by the expression of the dominant negative
AMPK mutant (Figure 4B). Therefore, these results
suggest that AMPK regulates Akt phosphorylation via
regulating PI3K or PTEN, an event independent of IRS1.
We then asked if the effect of ACIAR could be
blunted by Wortmannin, a specific inhibitor of PI3K.
Thus, we treated 3T3-F442a preadipocytes with AICAR
or insulin together with Wortaminnin. Figure 5 shows
that Wortmainnin suppressed AICAR-induced Akt
phoshorylation to an extent that is similar to its effect
on insulin. To assess if PTEN is involved in AMPK reg-
ulation of Akt activation, we made stable cell lines
expressing the dominant negative mutant PTEN C124S.
A ss h o w ni nF i g u r e6 ,t h ee x p r e s s i o nl e v e lo fP T E N
C124S reached approximately 10 times the endogenous
protein; however, it did not display a significant effect
on either insulin or AICAR-stimulated Akt activation. In
a parallel experiment, the endogenous PTEN was
knocked down with its shRNA by about 50%, which also
did not yield an evident effect on Akt activation (data
Figure 1 Effect of AICAR on insulin-stimulated phosphorylation of the PI3K pathway. 3T3-F442a preadipocytes were differentiated into
adipocytes. A. The cells were treated with or without AICAR (AI) (1 mM, 2 h), followed by insulin (Ins) (100 nM, 15 min) and equal amounts of
cell lysates were immunoprecipitated with antibodies against IRS1 and assayed on the associated PI3K activity. The radiolabeled PIP3 lipids were
resolved on thin layer chromatography and exposed to X-ray film. The autoradiogram represents one of a triplicate experiment. The PIP3 spots
were excised and counted in liquid scintillation. The graph denotes the average CPM of labeled PIP3 (n = 3, mean ± SD). B. In parallel to A,
protein samples were run onto SDS-PAGE and blotted with antibodies, as indicated.
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that AMPK regulates PTEN to impact on Akt activation.
Therefore, they suggest that AMPK activates Akt via
regulating PI3K.
Discussion
I nt h ep r e s e n ts t u d yw ee x p l o r e dt h em e c h a n i s m sb y
which AMPK enhances insulin sensitivity. We observed
that AICAR, a cell permeable metabolic precursor of the
AMPK activator ZMP, enhanced insulin-stimulated Akt
activation. In contrast, it impeded the ability of insulin
to activate mTOR, a critical kinase for protein synthesis
and cell growth. All these effects were suppressed by a
dominant negative mutant of AMPK a1 catalytic subu-
nit. Most intriguingly, our data provide new evidence
that AMPK appears to activate Akt by regulating PI3K,
instead of PTEN and IRS1.
It is well established that AMPK enhances insulin sen-
sitivity and ameliorates insulin resistance. However, the
underlying molecular mechanisms are not fully eluci-
dated. The net effect of AMPK on insulin signaling is
complex, with multiple targets involved depending on
the cellular context. Although a few studies have shown
that AMPK inhibits Akt [24], many found a positive
effect [7,8,11,15,25]. Thus, AMPK activators such as
AICAR, metformin or adiponectin enhance the effect of
insulin on Akt activation, an event that is inhibited by
overexpression of dominant negative mutant of AMPK
[7,8,11,15,25]. A previous study has shown phosphoryla-
tion of S789 on IRS1 in vitro by AMPK and in vivo by
AICAR in C2C12 myotubes [4], leading to an increase
in IRS1-associated PI3K activity without changes in
phosphorylation of tyrosine residues on IRS1 and its
association with p85 regulatory subunit of PI3K. In con-
trast, Qiao and coworkers have reported that phosphor-
ylation of S789 is associated with insulin resistance,
which is not attributed to AMPK [5]. In addition, Tzat-
sos and Tsichlis have reported that AMPK activation
induces phosphorylation of IRS1 at S794, leading to an
inhibition of PI3K/Akt signaling [6]. The reason under-
lying this discrepancy is currently unclear. Although our
study showed that AMPK activation enhanced insulin-
stimulated IRS1-associated PI3k activity and subsequent
activation of Akt, this probably occurs through regula-
tion of PI3K. This is supported by three lines of evi-
dence. First, Akt is directly activated by treatment of
cells with AICAR in the absence of insulin and sup-
pressed by Wortmannin. Second, AICAR increases the
level of PIP3. Third, overexpression of the dominant
negative mutant of PTEN does not seem to exert any
Figure 2 Dominant negative mutant of AMPK a1 subunit suppresses the effect of AICAR. 3T3-F44a preadipocytes were stably infected
with lentivirus expressing a dominant negative mutant of AMPK a1 catalytic subunit (DNa1) tagged with Flag epitope or a control virus
(Empty). A. The cells were treated with AICAR and insulin, as described for Figure 1, and assayed for immunoblot with antibodies, as indicated. B.
Expression of DNa1 diminishes the endogenous counterpart. The cell extracts containing empty vector (E) or the AMPK mutant (DN) were
immunoprecipitated (IP) with anti-flag antibody and equal amounts of pre-IP and post-IP extracts were blotted with anti-flag and anti-AMPK a1
antibodies, respectively. b-actin blot was used as an internal control.
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Page 4 of 9Figure 3 AMPK promotes Akt phosphorylation independent of IRS1. A. 3T3-F44a preadipocytes were treated with AICAR (1 mM, 2 h),
followed by EGF (10 ng/ml, 15 min) and the cell extracts blotted with antibodies, as indicated. B. 3T3-F44a preadipocytes containing DNa1o r
the empty viral vector were incubated with AICAR (1 mM) for different time, and the cell extracts blotted with antibodies, as indicated.
Figure 4 AMPK activation stimulates production of PIP3. 3T3-F44a preadipocytes bearing empty lentiviral vector (A) or the dominant
negative mutant of AMPKa1 subunit (B) were treated with AICAR (1 mM, 4 h) or insulin (100 nM, 15 min). Cells were immunostained with anti-
PIP3 monoclonal IgM antibody and counter-stained with DAPI for visualization of cell nuclei. Cells with empty viral vector accumulated PIP3
when treated with AICAR, as well as insulin (A). The AICAR induced PIP3 accumulation was not seen in the cells containing the AMPK mutant,
whereas the effect of insulin was not affected (B). Scale bar: 63.4 μm.
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surprising to us, which is contrary to existing dogmas
and probably reflects a cell-type difference. Our findings
are in line with those of Ouchi et al, where it has been
shown that adiponectin activates Akt in endothelial
cells, which is dependent on AMPK and suppressed by
PI3K inhibitor-LY294002 [7,8,11,15,25].
Hyperactivation of the mTOR-mediated pathway(s)
has been observed in insulin desensitizing events and
insulin resistant animal models [26-31]. This can be pre-
vented or reversed by rapamycin [30,31]. Likewise, dele-
tion of S6K1 alleles increases insulin sensitivity and
protects mice against age- and diet-induced obesity [32].
The inhibitory effect of mTOR/S6K1 on insulin
signaling correlates with increased S/T phosphorylation
of IRS1 at three sites, S307, S636/S639. Recent studies
have established that activated AMPK inhibits mTOR by
phosphorylation of TSC2, a negative regulator, and Rap-
tor, a positive regulator of mTOR, respectively [20-22].
Conclusion
Our present study has demonstrated that AMPK
enhances insulin sensitivity via at least two mechanisms;
first, it is involved in direct regulation of PI3K and sec-
ond, it inhibits mTOR/S6K to suppress negative feed-
back loop on the regulation of IRS1. While this latter
mechanism has been recently defined, it is not clear
how AMPK regulates PI3K. As there are several
Figure 5 Akt Activation by AICAR is suppressed by Wortmannin. A. 3T3-F44a preadipocytes were incubated with Wortminnin (Wort, 0.5 μM,
30 min), followed by AICAR (1 mM, 4 h) or insulin (100 nM, 15 min). The cell extracts were blotted with antibodies, as indicated. B. 3T3-F44a
preadipocytes were treated with Wortmannin at different doses, as indicated, for 30 min and followed by treatment with AICAR or insulin, as
described for A. Cell extracts were blotted with antibodies, as indicated.
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which isoform of PI3K is the target of AMPK and how
AMPK regulates its activity.
Methods
Materials
Antibodies against phospho- and nonphospho-proteins
of Akt, S6K1, S6, AMPK, and ACC were purchased
from Cell Signaling Technology (Danvers, MA). Antibo-
dies for IRS1 were from Millipore (Billerica, MA).
Mouse monoclonal IgM antibody against PIP3 was pur-
chased from Echelon Bioscience (Salt Lake City, UT).
Cyanine-3-conjugated goat anti-mouse antibody was
purchased from Jackson Immunoresearch (West Grove,
PA). Alexa Fluor 488 donkey anti-rabbit IgG was from
Invitrogen (Carlsbad, CA). DAPI and trisacryl protein A
beads were purchased from Pierce (Rockford, IL). PI
(4,5)P2 was from Sigmaaldrich (St. Louis, MO).
32P-g-
ATP was from PerkinElmer (Fremont, CA).
Cell culture
3T3-F442a and 3T3-L1 fibroblasts were grown and dif-
ferentiated as described previously [33]. Cells were used
8 to 12 days after differentiation [34]. C4-2 prostate can-
cer cells were purch a s e df r o mA m e r i c a nT y p eC u l t u r e
Collection and cultured in RPMI1640 containing 10%
fetal bovine serum in 5% CO2 incubator.
Plasmid DNA construction and transfection
The cDNA for dominant negative mutant of human AMPK
a1 catalytic subunit was kindly provided by Dr. Carling [23]
and cloned by PCR into a lentiviral vector where a flag epi-
tope was added to the amino terminus of the a1 mutant.
Lentivirus was prepared and the cells infected as described
previously [35,36]. The cDNA for PTEN (C124S) in pSG5L
(Addgene, Cambridge, MA) was digested with BamHI and
EcoRI and subcloned into the same Lentiviral vector as
used for AMPKa1 (TET-OFF) [35,36].
Immunoblot
Cell extracts were separated by SDS-PAGE and electro-
phoretically transferred to immobilon, as described pre-
v i o u s l y[ 3 4 ] .T h em e m b r a n e sw e r eb l o c k e da n d
sequentially incubated with specific primary antibodies
and second antibodies conjugated with horseradish per-
oxidase. Immunoreactive bands were visualized by ECL.
Immunofluoresent staining
3T3-F442a cells were cultured on coverslips pretreated
with poly-L-lysine. Immunostaining was carried out, as
previously described [34]. In brief, the cells were fixed
in 4% paraformaldehyde in PBS and then washed with
PBS. For PIP3 staining, after blocked with 10% normal
goat serum (NGS) for 30 min, samples were incubated
with mouse anti-PIP3 monoclonal antibody at 1:100
dilution for 2 h and non-immune mouse IgM was used
as a negative control. After washing 3 times with PBS,
the samples were incubated with Cyanine-3-conjugated
goat anti-mouse antibody at 1:500 dilution for 1 h. All
antibodies were diluted in PBS containing 2% NGS.
After immunofluorescent staining, the cells were also
counterstained with DAPI (0.5 μg/ml for 5 min) to
d e t e c tt h en u c l e ia n dt h ec o v e r s l i p sw e r em o u n t e di n
spectrometric grade glycerol and sealed with nail polish.
Fluorescent images were taken under Deltavision micro-
scope (Applied Precision, Issaquah, Washington).
Figure 6 Inhibition of PTEN does not affect AMPK-induced activation of Akt. 3T3-F44a preadipocytes stably infected with the dominant
negative PTEN (C124S) were treated with AICAR, insulin or together, as described for Figure 1, and the cell extracts were blotted with
antibodies, as indicated.
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The assay was performed according to a protocol pre-
viously described [34]. Briefly, cell extracts were immuno-
precipitated with antibodies against IRS1 preimmobilzed
in trisacryl protein A beads. The immunocomplex was
incubated with PI(4,5)P2 and
32P-g-ATP. The labeled pro-
ducts were extracted, separated by thin-layer chromatogra-
phy and exposed to X-Ray film. The PI(3,4,5)P3 spots were
excised and measured by scintillation counting.
Abbreviation list
ACC: acetyl coA carboxylase; AICAR: 5-aminoimida-
zole-4-carboxamide 1-D-ribonucleoside; AMPK: 5’AMP-
activated protein kinase; Akt: protein kinase B; CaMKK:
calmodulin-dependent protein kinase kinase; EGF: epi-
dermal growth factor; IRS1: insulin receptor substrate-1;
PAGE: polyacrylamide gel electrophoresis; PIP3: Phos-
phatidylinositol (3,4,5)-trisphosphate; PI3K: phosphoino-
sitide 3-kinase; PDK1: Phosphoinositide-dependent
kinase-1: PTEN: phosphatase and tension homologue;
mTOR: mammalian target of rapamycin; TORC: mTOR
complex; S6: ribosome S6; S6K1: ribosome S6 kinase 1.
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